In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate ...

The trial has enrolled 99 subjects from various centres globally to assess the efficacy and safety of the therapy.

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Updated guidance offers evidence-based strategies to optimize the diagnosis and treatment of non-metastatic upper tract ...

ASCO 2025 phase 1b/2 study assessing 9MW2821, nectin-4 antibody drug conjugate, toripalimab in treatment-naïve patients, locally advanced or metastatic urothelial carcinoma.